OBJECTIVE: Pulmonary fibrosis is a major cause of death in scleroderma patients. Previous studies have shown an increase in CD8+ T cells in the lungs of scleroderma patients. In the present study, we sought to determine whether activated CD8+ T cells contribute to pulmonary fibrosis in scleroderma patients through the production and activation of profibrotic mediators. METHODS: CD8+ cells were isolated from bronchoalveolar lavage fluid obtained from 19 scleroderma patients and 7 healthy subjects. The phenotype of these cells was determined using DNA array technology. Expression of selected genes was confirmed in real-time polymerase chain reaction and enzyme-linked immunosorbent assay experiments. RESULTS: Hierarchical clustering of gene expression profiles revealed 2 groups of subjects. Group 1 consisted of 11 patients (8 with and 3 without lung inflammation). Group 2 consisted of 15 subjects (7 healthy controls and 2 patients with and 6 without lung inflammation). Gene expression in group 1 indicated T cell activation, a type 2 phenotype, production of profibrotic factors and matrix metalloproteinases, and reduced activation-induced cell death. Increased expression of beta6 integrin messenger RNA by CD8+ T cells in group 1 suggested the possibility that these T cells might induce cell-contact-dependent activation of latent transforming growth factor beta (TGFbeta). CONCLUSION: A subset of scleroderma patients at higher risk of progressive lung disease have activated, long-lived CD8+ T cells in their lungs that could promote fibrosis directly, through production of profibrotic factors such as interleukin-4 and oncostatin M, as well as indirectly, through activation of TGFbeta.
OBJECTIVE:Pulmonary fibrosis is a major cause of death in sclerodermapatients. Previous studies have shown an increase in CD8+ T cells in the lungs of sclerodermapatients. In the present study, we sought to determine whether activated CD8+ T cells contribute to pulmonary fibrosis in sclerodermapatients through the production and activation of profibrotic mediators. METHODS: CD8+ cells were isolated from bronchoalveolar lavage fluid obtained from 19 sclerodermapatients and 7 healthy subjects. The phenotype of these cells was determined using DNA array technology. Expression of selected genes was confirmed in real-time polymerase chain reaction and enzyme-linked immunosorbent assay experiments. RESULTS: Hierarchical clustering of gene expression profiles revealed 2 groups of subjects. Group 1 consisted of 11 patients (8 with and 3 without lung inflammation). Group 2 consisted of 15 subjects (7 healthy controls and 2 patients with and 6 without lung inflammation). Gene expression in group 1 indicated T cell activation, a type 2 phenotype, production of profibrotic factors and matrix metalloproteinases, and reduced activation-induced cell death. Increased expression of beta6 integrin messenger RNA by CD8+ T cells in group 1 suggested the possibility that these T cells might induce cell-contact-dependent activation of latent transforming growth factor beta (TGFbeta). CONCLUSION: A subset of sclerodermapatients at higher risk of progressive lung disease have activated, long-lived CD8+ T cells in their lungs that could promote fibrosis directly, through production of profibrotic factors such as interleukin-4 and oncostatin M, as well as indirectly, through activation of TGFbeta.
Authors: Taylor A Doherty; Pejman Soroosh; Naseem Khorram; Satoshi Fukuyama; Peter Rosenthal; Jae Youn Cho; Paula S Norris; Heonsik Choi; Stefanie Scheu; Klaus Pfeffer; Bruce L Zuraw; Carl F Ware; David H Broide; Michael Croft Journal: Nat Med Date: 2011-04-17 Impact factor: 53.440
Authors: S P Atamas; I G Luzina; J Ingels; J Choi; W K Wong; D E Furst; P J Clements; A E Postlethwaite Journal: Clin Exp Immunol Date: 2010-09 Impact factor: 4.330
Authors: T Bohgaki; Y Amasaki; N Nishimura; M Bohgaki; Y Yamashita; M Nishio; K-I Sawada; S Jodo; T Atsumi; T Koike Journal: Ann Rheum Dis Date: 2005-08 Impact factor: 19.103
Authors: Natalia Nacu; Irina G Luzina; Kendrick Highsmith; Virginia Lockatell; Kerill Pochetuhen; Zachary A Cooper; Michael P Gillmeister; Nevins W Todd; Sergei P Atamas Journal: J Immunol Date: 2008-04-01 Impact factor: 5.422